Swipe om te navigeren naar een ander artikel
This study assessed the construct validity of the Health Utilities Index Mark 2 (HUI2) and Mark 3 (HUI3) in the context of chronic kidney disease (CKD) and compared their ability to discriminate between groups of patients with varying disease severity.
The HUI2 and HUI3 were correlated with the Medical Outcomes 36-Item Short-Form, Kidney Disease Quality of Life Questionnaire, and the Beck Depression Inventory II in 185 patients with stage 4 and 5 CKD.
About 86% of a priori hypotheses were confirmed for HUI2 and 95% for HUI3, providing support for the construct validity of both measures. Mean (SD) overall utility score for the HUI2 was 0.74 (0.20), significantly higher than that for the HUI3, 0.58 (0.26) (P < 0.001). The cognitive, emotion, and pain attributes of the HUI3 were able to identify a significantly greater proportion of patients with impairment compared to the HUI2.
The results are consistent with construct validity for the HUI2 and HUI3 in patients with stage 4 and 5 CKD. However, the HUI3 appears to have superior psychometric properties compared with the HUI2 in this patient population.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Hays, R. D. (1998). R36 H.S.I. Rand 36—36 health status inventory. Harcourt Brace & Company.
Hays, R. D., Kallich, J. D., Mapes, D. L., Coons, S. J., Amin, N., Carter, W. B., et al. (1997). Kidney disease quality of life short form (dkqol-sf), version 1.3: A manual for use and scoring. Santa Monica, CA: RAND.
Annual Data Report. (2007). Atlas of end-stage renal disease in the United States. American Journal of Kidney Diseases, 49(Supplement 1), S1–S239.
Lenert, L., & Kaplan, R. M. (2000). Validity and interpretation of preference-based measures of health-related quality of life. Medical Care, 38(9 Suppl), II138–II150. PubMed
Feeny, D., Torrance, G. W., & Furlong, W. (1996). Quality of life and pharmacoeconomics in clinical trials. In B. Spilker (Ed.), Health utilities index (pp. 239–51). Philadelphia, PA: Lippincort-Raven.
Ware, J. E. (1993). SF-36 Health survey: Manual and interpretation guide. Boston, MA: New England Medical Centre.
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). BDI-II manual (2nd ed.). San Antonio, Texas: Harcourt Brace.
Newmann, S. P. (2002). A randomised controlled trial of a psychological intervention to promote emotional expression and adaptation in individuals with chronic renal failure (CRF) and end stage renal disease (ESRD). UK: National Research Registry.
Fayers, P. M., & Machin, D. (2000). Quality of life: Assessment, analysis and interpretation. Willey.
Birbeck, G. L., Kim, S., Hays, R. D., & Vickrey, B. G. (2000). Quality of life measures in epilepsy: how well can they detect change over time? Neurology, 54(9), 1822–1827. PubMed
Canadian Organ Replacement Register. (2002). Dialysis and renal transplantation. Ottawa, Ontario: Canadian Institute for Health Information. Report No.: 2001 Report.
Hopman, W. M., Towheed, T., Anastassiades, T., Tenenhouse, A., Poliquin, S., Berger, C., et al. (2000). Canadian normative data for the SF-36 health survey. CMAJ, 163(3), 265–271. PubMed
Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993). Measuring health-related quality of life. Annals of Internal Medicine, 118(8), 622–629. PubMed
Davison, S. N., Jhangri, G. S., & Feeny, D. (2008). Comparing the health utilities index mark 3 (HUI3) with the short-form 36 preference-based SF-6D in chronic kidney disease. Value in Health (in press).
- Evidence on the construct validity of the Health Utilities Index Mark 2 and Mark 3 in patients with chronic kidney disease
Sara N. Davison
Gian S. Jhangri
David H. Feeny
- Springer Netherlands